These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17606720)

  • 1. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer.
    Kim JH; Bogner PN; Ramnath N; Park Y; Yu J; Park YM
    Clin Cancer Res; 2007 Jul; 13(13):3875-82. PubMed ID: 17606720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target.
    Kim JH; Bogner PN; Baek SH; Ramnath N; Liang P; Kim HR; Andrews C; Park YM
    Clin Cancer Res; 2008 Apr; 14(8):2326-33. PubMed ID: 18413821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer.
    Yang H; Wang W; Zhang Y; Zhao J; Lin E; Gao J; He J
    Clin Lung Cancer; 2011 May; 12(3):166-71. PubMed ID: 21663859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
    Zhang Z; Ma J; Li N; Sun N; Wang C
    Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
    Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
    Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology.
    Kim YJ; Ahn JY; Liang P; Ip C; Zhang Y; Park YM
    Cancer Res; 2007 Jan; 67(2):546-54. PubMed ID: 17234762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.
    Herbst RS; Yano S; Kuniyasu H; Khuri FR; Bucana CD; Guo F; Liu D; Kemp B; Lee JJ; Hong WK; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):790-7. PubMed ID: 10741698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-negative expression of Nrf2 and NQO1 predicts superior outcomes in patients with non-small cell lung cancer.
    Tong YH; Zhang B; Yan YY; Fan Y; Yu JW; Kong SS; Zhang D; Fang L; Su D; Lin NM
    Oncotarget; 2017 Jul; 8(28):45750-45758. PubMed ID: 28501854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
    Bonnesen B; Pappot H; Holmstav J; Skov BG
    Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
    Yang J; Liu H; Wang H; Sun Y
    Pathol Res Pract; 2013 Aug; 209(8):490-4. PubMed ID: 23827213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome.
    Zhang L; Chen J; Ke Y; Mansel RE; Jiang WG
    Int J Mol Med; 2006 May; 17(5):937-44. PubMed ID: 16596284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer.
    Yu CJ; Shun CT; Yang PC; Lee YC; Shew JY; Kuo SH; Luh KT
    Am J Respir Crit Care Med; 1997 Apr; 155(4):1419-27. PubMed ID: 9105088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of survivin and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery.
    Tang XP; Li J; Yu LC; Chen YC; Shi SB; Zhu LR; Chen P
    Lung Cancer; 2013 Aug; 81(2):273-9. PubMed ID: 23756092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CXCR4 and Nrf2 expressions in non-small cell lung cancer and their clinical implications].
    Hu T; Yao Y; Yu S; Guo H; Tian T; Han L; Wang W; Guo Q; Wang J; Nan K; Wang S
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Feb; 34(2):153-8. PubMed ID: 24589587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.
    Koike T; Koike T; Yoshiya K; Tsuchida M; Toyabe S
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):372-8. PubMed ID: 23870323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.